Disease states, such as breast cancer, arise from the disruption of chromatin, the central DNA-protein structures that package human genetic material. Mounting evidence from genome-wide studies across cancers show that Polycomb-mediated repression of sets of genes, called Polycomb modules, is strongly linked to a poor prognosis. We developed a synthetic transcriptional activator to release silenced genes from the repressed state. The Polycomb-based Transcription Factor (PcTF) is a synthetic effector that accumulates at methyl-histone marks and regulates hundreds of gene targets, including tumor suppressors. We recently reported the activity of PcTF in bone, blood, and brain sarcoma-derived model cell lines. Here, we expand our investigation of PcTF to three breast cancer-derived cell lines. We expressed PcTF in drug-responsive (MCF-7, BT-474) and nonresponsive triple negative (BT-549) breast cancer cell lines. RNA-seq showed that hundreds of genes were up-or down-regulated by PcTF as early as 24 hours after transfection. BT-549, the triple-negative cancer cell line, showed the highest number of PcTF-activated genes. We demonstrate the anti-cancer potential of PcTF by identifying 15 tumor suppressor genes that are upregulated across the three cell types. The data also provide new mechanistic insights into the relationship between chromatin organization and PcTF-mediated regulation of genes. Our results have exciting implications for cancer treatment with engineered biologics.
INTRODUCTION
Eukaryotic chromosomes are organized as chromatin, a dynamic network of interacting proteins, DNA, and RNA in eukaryotic nuclei. These interactions regulate gene transcription and coordinate distinct, genome-wide expression profiles in different cell types. Chromatin mediates epigenetic inheritance [1, 2] by regulating expression states that persist through cellular mitosis and in generations of sexually reproducing organisms [3, 4] . Trimethylation of histone H3 -a component of the nucleosome protein octamer core, the fundamental subunit of chromatin -at lysine 27 (H3K27me3) plays a central role in the epigenetic regulation of genes that control cell differentiation [5, 6] . Several landmark studies have revealed that hyperactivity of the histone-methyltransferase enhancer of zeste 1 and 2 (EZH1, EZH2), which generates H3K27me3, is a feature shared by many types of cancer (recently reviewed in [7] ). In breast cancer, elevated EZH2 has been linked to cell proliferation and metastasis [8, 9] and a poor prognosis for breast cancer patients [10] [11] [12] [13] . In stem cells and cancer cells, EZH2 generates the repressive H3K27me3 mark at nucleosomes near the promoters of developmental genes to prevent differentiation and maintain the proliferative state in stem cells or to generate neoplasia in cancer (reviewed in [5] ). Polycomb Repressive Complex 1 (PRC1) binds to the H3K27me3 mark through the polycomb chromodomain (PCD) motif of the CBX protein to stabilize the repressed state. Silencing is reinforced by other chromatin regulators including histone deacetylase (HDAC) and DNA methyltransferase (DMT) [14] .
The PRC module, a group of genes that is silenced by H3K27me3 and Polycomb transcriptional regulators [15, 16] , is a high priority for cancer research and the development of epigenetic drugs. Epigenetic therapy targets aberrant chromatin within cancer cells. This approach overcomes the problem of resistance to hormone therapy, which requires the presence of specific transmembrane receptors on the surfaces of cancer cells. Relatively high expression or upregulation of PRC module genes is associated with a non-proliferative state, cell adhesion, organ development, and normal anatomical structure morphogenesis [15] . Knockdown (depletion) of chromatin proteins (reviewed in [16, 17] ) and inhibition of Polycomb proteins with low molecular weight compounds and peptides [18] [19] [20] stimulates expression of developmental genes and perturbs cancer-associated cell behavior. The success of epigenetic interventions in clinical trials [21, 22] demonstrates that mis-regulated chromatin is a druggable target in cancer. Basic research has revealed certain limitations for epigenetic inhibitor compounds. Inhibitors indirectly activate silenced genes by blocking repressors, generate incomplete conversion of silenced chromatin into active chromatin [23, 24] , interact with off-target proteins outside of the nucleus [25] , and do not affect resistant Polycomb protein mutants [26] [27] [28] . These limitations can be addressed with alternative molecular technologies.
Biologics, therapies composed of macromolecules such as proteins, are richer in biochemical information compared to low molecular weight compounds. Until recently, none have been designed to decode epigenetic information in cancer cells. To this end, we developed the Polycomb-based Transcription Factor (PcTF), which binds H3K27me3 [29] and recruits endogenous transcription factors to PRC-silenced genes. In bone, brain, and blood-cancer derived cell lines, PcTF expression stimulates transcriptional activation of several anti-oncogenesis genes [30] . PcTF-mediated activation leads to the eventual loss of the silencing mark H3K27me3 and elevation of the active mark H3K4me3 at the tumor suppressor locus CASZ1 . To advance PcTF towards medical translation, we sought to investigate the behavior of this protein in breast cancer cells lines that have been established as models for tumorigenesis [31] [32] [33] .
Here, we extend our investigation of PcTF target genes to three breast cancer-relevant cell lines. First, we investigated the transcription profiles of predicted PRC module genes in drug-responsive (MCF-7, BT-474) and nonresponsive triple negative (BT-549) breast cancer cell lines.
cells from patient samples [34, 35] . We show that the transcription profiles of the untreated breast cancer cells are distinct from MCF10A, a breast tissue-derived control cell line. We also show that predicted Polycomb-regulated genes are repressed in the breast cancer cells compared to MCF10A.
Over expression of PcTF in transfected breast cancer cells led to the upregulation of dozens of genes, including many predicted PRC module genes and 15 well-characterized tumor suppressor genes, as early as 24 hours after transfection. The transcriptome of BT-549 (triple-negative) showed the highest degree of PcTF-sensitivity. Our results also provide new mechanistic insights into the relationship between chromatin structure and activation of genes by an artificial regulator. We observed that PcTF-sensitive genes are enriched for silencing marks and low levels of activation-associated chromatin marks, suggesting that PcTF regulates genes that are poised for activation.
RESULTS

Differential regulation of genes in breast cancer cell lines
To determine expression levels of predicted PRC module genes, we profiled the transcriptomes of three breast cancer cell lines and the non-invasive, basal B cell line MCF10A [36, 37] using next-generation deep sequencing of total RNA (RNA-seq). MCF7, BT-474, and BT-549 represent luminal A, luminal B, and basal B subtypes of breast cancer, respectively (Table 1 ) [31] . Previous studies have shown that gene expression profiles distinguish two major categories of cancer cell lines, luminal and basal, in patient-derived samples [38, 39] . The basal class exhibits a stem-cell like expression profile [40] , which is consistent with high levels of Polycomb-mediated repression at genes involved in development and differentiation [41, 42] . Levels of the repressor protein EZH2 and the histone modification that it generates (H3K27me3) are elevated in MCF7, BT-474, and BT-549 compared to non-metastatic cells such as MCF10A (Table 1) . A mechanistic link between Polycomb-mediated repression and tumor aggressiveness has been supported by a study where stimulation of the phosphoinositide 3-kinase (PI3K) signaling pathway, which induces a metastatic phenotype in MCF10A, is accompanied by increased H3K27me3 at several target genes [43, 44] . We hypothesized that known Polycomb-repressed genes (the PRC module) would be down-regulated in the cancerous cell lines compared to MCF10A. MCF10A CRL-10317 Non-invasive/ Basal B ER-, PRn/a n/a Differential expression between cell lines for individual genes (Fig. S1 ) followed similar trends as those observed for the global JSD analysis. We used an expression comparison algorithm (Cuffdiff [50] ) to identify genes that were differentially expressed (2-fold or greater difference in expression, q value ≤ 0.05) or similarly expressed (less than 2-fold difference, q value ≤ 0.05) between cell types.
Comparisons that included MCF10A showed the highest numbers of differentially-expressed genes, as well as the lowest numbers of similarly expressed genes. This result further supports transcriptional differences between the cancerous cell lines and MCF10A (Fig. S1 ).
Next, we determined expression levels within groups of predicted PRC-regulated genes and observed that expression within these subsets is lower in the three cancer cell types than in MCF10A.
We used data from other breast cancer cell line studies of MCF7 and MDA-MB-231 to classify a subset of PRC target genes based on H3K27me3 enrichment or binding of EZH2, an enzyme that generates the H3K27me3 mark (see Methods). Only 245 gene IDs were shared between the H3K27me3 and EZH2 subsets. Although these two groups are mostly distinct, both showed low median expression values (FPKM < 2), which suggests epigenetic repression (Fig. 1B) 
PcTF-responsive genes include PRC module genes and other loci
We investigated PcTF-mediated gene regulation in the three breast cancer cell lines by profiling the transcriptomes of PcTF-expressing cells (Fig. 2) . We transfected cells with PcTF-encoding plasmid DNA (previously described [30] ) via Lipofectamine LTX and and allowed transfected cells to grow for 24, 48, and 72 hours before extracting total RNA for sequencing. RNA-seq reads were aligned to a human reference genome GRCh38 that included the coding region for PcTF (see Methods). No reads aligned to the PcTF coding sequence in control, untransfected cells. In the transfected cells, PcTF expression levels were highest at 24 hours and decreased 1.6 to 5.5-fold every 24 hours ( Fig. 2A ).
We observed a similar trend with other cancer cell lines in a previous study [30] . One outlier sample, a replicate for BT-474 cells expressing PcTF for 48 hours, had a markedly different PcTF expression level ( Fig.  2A ) and genome-wide transcription profile ( Fig. S2 ) and was therefore omitted from further analyses. Different subsets of genes were up-or down-regulated at least two fold ( q value ≤ 0.05) early, late, or across all time points during PcTF expression (Fig. 2B ). Of the genes that showed at least a two-fold change in either direction, the vast majority were up-regulated (Fig. 2B) . Genes that were significantly up-or down-regulated at least 2-fold at all three time points ( Nineteen genes were upregulated at least 2-fold ( q value ≤ 0.05) at all time points in all three cell lines (Fig. 2C ). These genes are part of the interferon and innate immunity pathway: C19orf66 ,
DDX58, DTX3L, HERC6, IFI27, IFI44L, IFI6, IFIH1, ISG15, LGALS3BP, MX1, OAS1, OAS3, PARP9,
PARP14, PLSCR1, SP100, UBE2L6 , and XAF1 . The most significantly enriched GO terms for this set include defense response to virus, negative regulation of viral life cycle, response to stimulus, and immune system process ( Fig. S4) . Four of these genes ( IFI6, MX1, OAS3 , and UBE2L6 ) may have become activated as a nonspecific response to foreign plasmid DNA and RNA, as previously reported by others [54] [55] [56] [57] [58] . These genes may also be direct targets of PcTF. MX1 , HERC6 , and UBE26L belong to the PRC module groups shown in Figure 1 (panels B and C). Other studies have linked high levels of expression from interferon pathway genes with a non-cancerous phenotype. In breast cancer, an immune response gene-expressing subgroup, which includes ISG15 , MX1 , and other interferon genes, has been associated with improved prognosis in triple negative breast cancers [59, 60] . Therefore, our results suggest that PcTF shifts the transcription profiles of breast cancer cells towards an anti-cancer state. Our discovery of 19 commonly upregulated genes indicates that diverse cancer subtypes can be similarly affected by a single synthetic transcriptional regulator.
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Genes become upregulated over time in the presence of stable PcTF levels
We sought to determine the dynamics of transcriptional regulation at PcTF-regulated genes. Using transient transfections, we established that PcTF-mediated activation of genes could be detected over background at multiple time points. However, in this experiment PcTF levels decreased over time ( Fig.   2A ), which prevents us from distinguishing time-versus dose-dependent effects on gene regulation.
Therefore, we constructed stable transgenic MCF7 cell lines to enable constant expression of the fusion protein over time. Expression of PcTF or a control fusion protein that lacks the histone-binding domain (Pc Δ TF) was placed under the control of the rtTA activator, which binds to the pTet promoter in the presence of doxycycline (dox) (Fig. 3A) . Expression of rtTA was indicated by constitutive GFP expression, and inducible nuclear localization sequence-tagged PcTF was detected as a nuclear RFP signal in the presence of doxycycline (Fig. 3B ). We used quantitative reverse transcription PCR (qRT-PCR) to measure the expression levels of PcTF and a subset of PcTF-sensitive genes that were identified in the RNA-seq experiment (Fig. 2 ).
QRT-PCR using a universal mCherry-specific primer set confirmed that PcTF expression levels decreased over time in transiently transfected cells (Fig. 3C) as observed in the RNA-seq experiment ( Fig. 2A) . The stable transgenic cells showed low levels of fusion protein mRNA in the initial uninduced (dox-minus) state compared to untransfected MCF7 cells. Exposure to 1 μg/mL dox increased PcTF and Pc Δ TF levels by an order of magnitude. These levels were slightly higher than the For qRT-PCR analysis of PcTF target genes, we were able to design and validate specific assays for a subset of the PcTF-induced genes that were identified in the RNA-seq experiments. We selected transcripts that represented a range of basal expression levels, from low to high FPKM values, in the untreated state: XAF1 (2.9E-03), SAMD9L (0.03), GBP1 (0.31), CEACAM1 (0.96), CASP14 (1.14), and SP100 (14.57). XAF1 was the most strongly upregulated across all three time points (18 to 36-fold). This result agreed with the high fold-change values we observed in the RNA-seq experiment for transiently transfected cells (Fig. 2C) . The other five genes showed slight upregulation (1.4 to 1.8-fold) in response to dox-induced PcTF expression. The relatively weak response of these genes compared to XAF1 could be explained by a smaller dynamic range, where
genes may have been slightly upregulated prior to dox treatment since PcTF was detected at low levels before induction (Fig. 3C) .
In all cases except for SP100 , the truncated fusion protein Pc Δ TF did not upregulate the target .
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activation-associated marks
To investigate the contribution of local chromatin states to PcTF-mediated gene regulation, we compared chromatin modifications at several loci with the expression profiles of the corresponding genes. Previously, we showed that CASZ1 , a direct target of PcTF, was enriched for H3K27me3 up to 10 kb upstream of the promoter and showed an immediate (10 -24 hours) response to PcTF in a U-2 OS model cell line [30] . Here, we utilized the extensive public ChIP-seq data that is available for MCF7 to investigate chromatin modifications at PcTF-responsive genes. In untreated MCF7 cells, CASZ1 was expressed at a moderate level (FPKM = 9.75) and became upregulated up to 1.8-fold after 72 hours of PcTF expression (Fig. 4A) (Fig. 3B) . These data provide further evidence that PcTF acts upon a select subset of H3K27me3-enriched loci, as we previously observed in other cell lines [30] . Class 2
PcTF-responsive genes generally lack the H3K27 methylation mark and may represent downstream targets of the products expressed from direct PcTF targets.
To investigate potential off-target binding with a similar histone modification, we analyzed enrichment profiles for the mark H3K9me3. PCD peptides have shown some affinity for both H3K9me3 and H3K27me3 peptide tails in vitro [61, 62] . The gene subsets showed no significant differences in mean H3K9me3 enrichment (Fig. 4B) , a modification that is frequently found at .
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The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/186056 doi: bioRxiv preprint first posted online Sep. 7, 2017; constitutive pericentric heterochromatin and non-coding DNA [63] [64] [65] . We observed that PcTF-responsive genes tended to be distributed along chromosome arms rather than concentrated near centromeres (Fig. S4) . Fifteen of the 983 TSGs were upregulated across all three time points in at least one of the cell lines (Fig. 5B) . Information genecards.org [69] further validated the association of these 15 genes with tumor suppressor activity. Of the fifteen upregulated TSGs, seven belong to the breast cancer susceptibility (BRCA) pathway: CDKN1A , PML , ANGPTL4 , CEACAM1 , BMP2 , SP100 , TFPI2 .
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Cell line comparisons of RNA-seq FPKM values for the fifteen tumor suppressor genes showed that median expression was lower in untreated BT-474 and MCF7 than in the non-cancerous MCF10A cell line (Fig. 5A ). This result is consistent with the idea that epigenetic repression of TSGs supports a cancerous cell phenotype. In PcTF-expressing cells, the median expression of the fifteen tumor suppressor genes was increased at all time points compared to the untreated samples for each cancer cell line (Fig. 5A) . Interestingly, the median FPKM value for the 15 TSGs was higher in BT-549 than in MCF10A. We examined the expression levels of the individual genes and found that BMP2 , CEACAM1 , CDKN1A , DSP are lower in BT-549, as well as BT-474 and MCF7, than in MCF10A (Fig.   5B ). These genes become upregulated in PcTF-expressing cells.
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CONCLUSIONS & DISCUSSION
We have demonstrated that PcTF, a synthetic transcription factor that is designed to recognize H3K27me3, leads to broad changes in the transcription profiles of cell lines that represent different breast cancer subtypes. We hypothesized that genes enriched for Polycomb-associated chromatin marks would become up-regulated by PcTF. While many H3K27me3-enriched genes were upregulated in MCF7, many were non-responsive. Several genes that were not identified as Polycomb-enriched became up-regulated by PcTF. Enrichment of H3K9me3 did not distinguish PcTF-responsive genes, therefore we can rule out off-target binding which has been observed for PCD peptides in biochemical studies [61, 62] . At PcTF-responsive genes, levels of H3K4me3 and H3K27ac were higher than at silenced non-responsive genes, but RNA PolII was depleted compared to active non-responsive genes. Therefore, the chromatin at PcTF-responsive genes may support a low or intermediate expression state. Berrozpe et al. recently reported that Polycomb complexes preferentially accumulate at weakly expressed genes rather than strongly silenced or highly expressed genes [70] . In our experiments, specific PRC-regulated genes may have been expressed at low to intermediate levels and then further upregulated upon exposure to PcTF. Our analysis of PcTF-regulated genes and chromatin states paves the way for future studies to further resolve chromatin features that distinguish regulatable PRC-repressed genes in cancer cells.
Deregulation of histone-modifying enzymes contributes to epigenomic diversity in breast cancer cells [13] . Other factors can also contribute to transcription profile variations, such as differences in the abundance of wild type or mutated transcription factors, or mutations that impact the stability and turnover of RNA transcripts. Past work has begun to illuminate the relationship between phenotypic subclasses and transcription profiles [15, 36, 49, 71] . Such investigations help to elucidate cancer mechanisms and drug targets for more effective treatments. However, the link between transcriptome and phenotype is not entirely straight-forward. We observed that the transcription profile of BT-549 (invasive basal B) is more similar to MCF7 (luminal) than either were to BT-474 (luminal).
In contrast, other reports have shown clear distinctions between the transcription profiles and phenotypes of BT-549 and MCF7 [36, 49] . Differences in transcript profiling methods, our RNA-seq and JSD analysis versus the DNA oligomer arrays used by others, may account for this conflicting result. Further, we acknowledge that the JSD may be driven by a few genes with high expression and high variance, which could account for some of the patterns. Cancer cell transcriptome diversity poses a formidable challenge for the development of drugs that pinpoint specific genes and pathways. The results reported here demonstrate that PcTF co-regulates cohorts of genes, many of which are associated with anticancer functions, in diverse model breast cancer cell lines with different basal 
MATERIALS AND METHODS
DNA constructs
Plasmids were constructed to express fusion proteins either constitutively or in the presence of doxycycline. The plasmid for constitutive expression of PcTF, hPCD-TF_MV2 (KAH126), was constructed as previously described [79] . 
Preparation of total mRNA
Total messenger RNA was extracted from 90% confluent cells (~1-2x10 6 ). Adherent cells were lysed directly in culture plates with 500 μl TRIzol. TRIzol cell lysates were extracted with 100 μl chloroform and centrifuged at 12,000 xg for 15 min. at 4°C. RNA was column-purified from the aqueous phase (Qiagen RNeasy Mini kit 74104).
Quantitative reverse transcription PCR (qRT-PCR)
SuperScript III (Invitrogen) was used to generate cDNA from 2. (Fig. 3D ).
Transcriptome profiling with RNA-seq RNA-seq was performed using two biological replicates per cell type, treatment, and time point for transiently transfected cells and three replicates for untransfected MCF10A. Total RNA was prepared as described for qRT-PCR. 50 ng of total RNA was used to prepare cDNA via single primer isothermal amplification using the Ovation RNA-Seq System (Nugen 7102-A01) and automated on the Apollo 324 liquid handler (Wafergen). cDNA was sheared to approximately 300 bp fragments using the Covaris M220 ultrasonicator. Libraries were generated using Kapa Biosystem's library preparation kit 
Transcriptome analysis
RNA-seq reads were quality-checked before and after trimming and filtering using FastQC [81] .
TrimmomaticSE was used to clip bases that were below the PHRED-scaled threshold quality of 10 at the 5' end and 25 at the trailing 3' end of each read for all samples [82] . A sliding window of 4 bases was used to clip reads when the average quality per base dropped below 30. Reads of less than 50 bp were removed. A combined reference genome index and dictionary for GRCH38.p7 (1-22, X, MT, and non-chromosomal sequences) [83] that included the full coding region of the synthetic PcTF protein were created using Spliced Transcripts Alignment to Reference (STARv2.5.2b) [84] and the . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/186056 doi: bioRxiv preprint first posted online Sep. 7, 2017; picard tools (version 1.1.19) [85] . Trimmed RNA-seq reads were mapped, and splice junctions extracted, using STARv2.5.2b read aligner [84] . Bamtools2.4.0 [86] was used to check alignment quality using the 'stats' command. Mapped reads in BAM format were sorted, duplicates were marked, read groups were added, and the files were indexed using the Bamtools2.4.0 package. CuffDiff, a program in the Cufflinks package [53] , was used to identify genes and transcripts that expressed significant changes in pairwise comparisons between conditions. Fastq and differential expression analysis files are available at the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database (Accession GSE103520, release date September 8, 2017).
CummeRbund [53] was used to calculate distances between features and to generate graphs and charts (JSD plots). R ggplot2 [83, 87] and VennDiagrams [88] were used to generate heat maps and Venn diagrams respectively. The entire workflow is provided as a readme file at:
https://github.com/WilsonSayresLab/PcTF_differential_expression
Bioinformatics analyses and sources of public shared data
For the results shown in Figure 1B , genome-wide H3K27me3 enrichment in MCF7 cells, determined by chromatin immunoprecipitation followed by deep sequencing (ChIP-seq), was downloaded from the ENCODE project (accession UCSC-ENCODE-hg19:wgEncodeEH002922) [89] . We classified genes with a ChIP-seq peak within 5000 bp up or downstream of the transcription start site as H3K4me3 (ENCFF530LJW.bigWig), and RNA PolII (ENCFF690CUE.bam) and used to generate plots using DeepTools [90] (computeMatrix, plotProfile, plotHeatmap) in the Galaxy online platform at usegalaxy.org [91] . Prior to plotting, the RNA PolII data was converted to bigWig format using bamCoverage. Figure S4 was generated using REViGO [92] Unique differentially expressed genes were researched using GeneCards [69] and GOrilla analysis [93] . For the data shown in Figure S5 , REViGO [92] was used to compare the biological functions for the differentially expressed genes. The results in Figure 5 are based on human tumor suppressor genes (983 total) that are reported to show lower expressed in cancer samples of the Cancer Genome Atlas (TCGA) compared to the TCGA normal tissue samples was downloaded from https://bioinfo.uth.edu/TSGene/download.cgi . Of these 983 genes, 589 are breast cancer specific [67, 68] .
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